TrialFrontiers in medicine2026

Nimotuzumab combined with gemcitabine and nab-paclitaxel as first-line therapy for advanced pancreatic cancer: a single-arm, single-center Phase II prospective study.

Lin Lin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.